ClinicalTrials.gg
TerminatedNCT03615508Updated Mar 3, 2022Results posted

Exploration of Pupil Dilation in Horner's Patients Taking Flomax

A Phase 4 interventional study of 10% phenylephrine in Horner Syndrome, sponsored by Denver Health and Hospital Authority. Terminated at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Denver Health and Hospital Authority · Phase 4, Interventional, and Other

Why this study was terminated
incomplete enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is evaluating the pupil dilation of Horner's Patients who have ever taken an alpha blocker such as Tamsulosin. Patients will undergo eye dilation as would occur at a yearly eye examination, but their pupil dilation measurements will be recorded.

Read the detailed description

This study will enroll 10 participants who have a unilateral Horner's Syndrome AND have a history of taking an alpha blocker such as Tamsulosin. Participants will be recruited based on those two enrollment criteria, and after consenting they will undergo pupil dilation with 10% phenylephrine. Once fully dilated the pupil size will be measured. Pupil dilation size of the eye affected by the Horner's Syndrome will be compared to the eye not affected by Horner's. Primary study outcome is the comparative dilation size of the Horner's affected eye to the non affected eye in all subjects.

02

Conditions studied

  • Horner Syndrome

Keywords

  • Alpha blockers
  • Tamsulosin
03

In context

Lead sponsor

Denver Health and Hospital Authority is the lead sponsor of 84 studies on the registry; 4 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Horner's Syndrome
  2. History of taking an alpha blocker (tamsulosin/ terazosin/doxazosin/alfuzosin/silodosin) medication

Exclusion criteria

Exclusion Criteria:

  1. Subjects with untreated hypertension
  2. Subjects with thyrotoxicosis
  3. Pregnant women
  4. Prisoners
  5. Inability to consent
  6. Subjects with anatomical narrow angles who have never had a dilated exam
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Other
    10% phenylephrine

    All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.

    Drug: 10% phenylephrine

Interventions

  • 10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.

    Also known as: Phenylephrine 10%, Pupil Dilation

06

What researchers measure

Primary outcomes

  1. Pupil Size Measurements

    pupil dilation measurements will be taken of each eye at the eye examination.

    Time frame: 20-30 minutes after 10% phenylephrine has been placed in each eye.

07

Results

Posted Oct 14, 2020

Participant flow

Participant flow — Overall Study
Milestone10% Phenylephrine
Started1
Completed1
Not completed0

Outcome measures

PrimaryPupil Size Measurements

pupil dilation measurements will be taken of each eye at the eye examination.

Time frame:
20-30 minutes after 10% phenylephrine has been placed in each eye.

No measurements were reported for this outcome.

Adverse events

Collected over N/A - Adverse Events not Monitored/Assessed. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10% Phenylephrine———

Baseline characteristics

Study terminated, no patients analyzed; Data not reported for 1 participant for privacy reasons.

Age, Categorical
Age, Categorical10% Phenylephrine
<=18 years—
Between 18 and 65 years—
>=65 years—
Age, Continuous
Age, Continuous10% Phenylephrine
Sex: Female, Male
Sex: Female, Male10% Phenylephrine
Female—
Male—
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected10% Phenylephrine
Region of Enrollment
Region of Enrollment(participants)10% Phenylephrine
08

Study locations

2 sites
  • University of Colorado Hospital, Rocky Mountain Lions Eye Institute
    Denver, Colorado 80023, United States
  • Denver Health
    Denver, Colorado 80024, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in May 2019, 7 months.

Results were first posted in Oct 2020, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2018
First posted
Aug 3, 2018
StartActual
Sep 21, 2018
Primary completionActual
May 1, 2019
CompletionActual
May 1, 2019
Results first posted
Oct 14, 2020
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03615508
Lead sponsor
Denver Health and Hospital Authority
Responsible party
Cristos Ifantides, MD, MBA (Associate Professor, Department of Ophthalmology, Denver Health and Hospital Authority) — Principal investigator
First posted
Aug 3, 2018
Start date
Sep 21, 2018
Primary completion
May 1, 2019
Completion
May 1, 2019
Results posted
Oct 14, 2020
Last update
Mar 3, 2022

Study contacts

Cristos Ifantides, MD
principal investigator · Denver Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenylephrine

Start the discussion